teaser
Johnson & Johnson’s third-quarter profits fell about 8% because of a charge for cutting jobs, primarily in its stent-making and pharmaceuticals businesses, the company has said.
The company earned $2.5bn compared with a profit of $2.7bn during the same period last year.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Revenue rose to $14.9bn from $13.2bn, helped by strong results in international markets.
In July, the firm said it would reduce its global workforce by up to 4%, or up to 4,820 jobs, partly in order to cut costs due to falling sales of heart stents, plus looming patent expirations.
Copyright © PA Business 2007
